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Abstract
Not only is chronic hepatitis C virus (HCV) infection 
MINIREVIEWS
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a major public health problem, but also it can cause 
hepatocellular carcinoma and, more rarely, non-
Hodgkin’s lymphoma. These characteristics mean that 
HCV is the only virus infecting humans that is able to 
cause two different cancers. The fine pathogenetic and 
molecular mechanisms by which HCV induces these 
two malignancies are not completely clear. In the last 
decade, it has been shown that microRNAs (miRNAs), 
a class of 21-23-nucleotide molecules modulating post-
transcriptional gene expression, make an important 
contribution to the pathogenesis of several cancers 
and are also considered highly promising biomarkers. 
Here, we briefly describe the current knowledge about 
microRNAs’ involvement in HCV-related molecular 
oncogenesis. We decided to focus our attention on 
studies fully conducted on ex vivo  samples with this 
specific etiology, and on cultured cell lines partially 
or completely expressing the HCV genome. Some of 
the results reported in this review are controversial, 
possibly because of methodological issues, differences 
in sampling size and features, and ethnicity of patients. 
What is certain is that miRNAs play a remarkable role 
in regulating gene expression during oncogenetic 
processes and in viral infection. A clear understanding 
of their effects is fundamental to elucidating the 
mechanisms underlying virus-induced malignancies.
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Core tip: Not only is chronic hepatitis C virus (HCV) 
infection a major public health problem, but also it 
can cause hepatocellular carcinoma (HCC) and, more 
rarely, non-Hodgkin’s lymphoma. The mechanisms by 
which the virus induces these malignancies are remain 
unclear, however, it has become evident recently 
that small molecules regulating gene expression, the 
microRNAs, could be involved in these processes. 
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experimental anti-HCV drug (Miravirsen) targeting this 
miRNA[8-12].
At same time, the virus is responsible for the 
modulation of other cellular miRNAs. In fact, some 
authors have studied the effect of HCV proteins, 
mainly the core protein, on cellular miRNA regulation. 
The HCV core protein seems able to suppress the 
activity of Dicer, the enzyme that plays a key role in 
the production of mature miRNAs[13].
Some research conducted in vitro was designed 
to better understand the mechanisms by which HCV 
modulates the expression of miRNAs and promotes 
evolution towards malignancy. 
MiR-198 is downregulated in HCC. Decreased 
expression of miR-198 is linked to the progression 
of hepatocarcinogenesis and to the degree of liver 
injury[14]. An even more recent study conducted in vitro 
showed that miR-198 overexpression in hepatoma 
cells leads to a marked inhibition of cell growth and 
migration[15]. These results confirmed the crucial role of 
miR-198 in hepatocellular carcinogenesis, suggesting 
that it might act as a potent tumor suppressor by 
inhibiting cell proliferation and migration (Table 1).
Using miRNA array analysis, Ishida et al[16] demon-
strated that the expressions of miR-192/miR-215, 
miR-194, miR-320 and miR-491 were altered by HCV 
in human hepatoma cell lines. Of these, miR-192/
miR-215 and miR-491 were able to enhance the 
replication of HCV replicon, as well as HCV itself. 
A previous microarray analysis identified 108 
human miRNAs and 1247 mRNAs whose expression 
levels changed by more than 2.0-fold in response to 
HCV infection in a Huh7 cell line. These data indicated 
that combined miRNA and mRNA profiling might 
have superior potential as diagnostic and mechanistic 
features in hepatocarcinogenesis[17].
Salvi et al[18] identified differential expression 
of miRNAs in cirrhotic and non-cirrhotic HCCs. By 
generating a small RNA library in the human HCC cell 
line HA22T/VGH, the authors determined the expression 
levels of the most frequently cloned miRNAs in HCC 
tissues and in their peritumoral counterparts. This 
research used an in vitro approach to obtain interesting 
hints for the next part of the study conducted on HCC 
tissue samples. As better explained in the following 
section of this review about tissue sample studies, the 
authors observed miR-24 and miR-27a downregulation 
in HCCs from cirrhotic liver tissues compared with non-
cirrhotic liver samples and upregulation of miR-21.
Braconi et al[19], in an in vitro study with possible 
translational impact on clinical practice, hypothesized 
that HCV viral proteins could modify therapeutic 
responses to HCC by altering host cell miRNA expression. 
Using HepG2 cells stably transfected with the full-length 
HCV genome, these authors demonstrated a five-fold 
overexpression of miR-193b in these cells. One of the 
predicted targets of miR-193b is Mcl-1, an antiapoptotic 
protein able to modulate the response to Sorafenib; 
therefore, the authors speculated that cells expressing 
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The aim of this review was to establish order in the 
rich literature concerning microRNAs in HCC and 
lymphomas, by selecting only the results relating 
to HCV-induced cancers from the multiple-etiology 
analyses. 
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INTRODUCTION
Hepatitis C virus (HCV) infection is a major public 
health problem, with 170 million carriers worldwide 
and more than 300000 deaths each year attributable 
to this virus[1]. Hepatocellular carcinoma (HCC) is 
a major malignancy worldwide, being the second 
most frequent cause of cancer death in men and the 
sixth in women, and hepatocarcinogenesis is closely 
associated with HCV infection[2]. HCV is also involved 
in the pathogenesis of non-Hodgkin’s lymphoma 
(NHL)[3-5], although less frequently compared with 
HCC. These characteristics mean that HCV is the 
only virus infecting humans that is able to cause two 
different cancers. The exact processes by which HCV 
induces both HCC and NHL are a challenging topic for 
scientists, and although some progress has been made 
recently, many steps in these complex mechanisms 
remain unknown. 
In the last 10 years, the potential involvement of 
microRNA in the molecular pathogenesis of several 
diseases, including cancers, has been recognized. 
MicroRNAs (miRNAs) are endogenous 21-23 nucleo-
tides, non-coding RNA molecules, regulating post-
transcriptional gene expression by translational 
repression or mRNA cleavage[6]. MiRNAs can act both 
as oncogenes (oncomirs) or as tumor suppressors 
because their target genes can induce neoplastic 
transformation[7].
Our understanding of the role of miRNAs in molecular 
oncogenesis is expanding day by day; therefore, we 
will review the most interesting miRNAs involved in the 
pathogenesis of HCV-related malignancies, and highlight 
their role as biomarkers or their potential as therapeutic 
targets.
MICRORNAS IN HCV-RELATED HCC 
In vitro studies
Several studies on the relationship between HCV 
biology and host non-coding RNAs have demonstrated 
that HCV itself takes advantage of some miRNAs for 
its replication. The role of miR-122 in supporting HCV 
replication has already led to the development of an 
HCV proteins may better respond to this drug because of 
miRNA-dependent modulation of apoptosis. Therefore, 
manipulation of miRNA expression (i.e., using miR-193b 
mimetics) could be a useful strategy to enhance the 
response to chemotherapy in HCV-related HCC.
HCC tissue sample studies
MiRNAs play a pivotal role in HCV infection and in liver 
carcinogenesis, but only a few studies have specifically 
investigated the expression pattern of miRNAs in HCV-
associated HCC tissues. While many papers describe 
deregulation of miRNAs in HCC tissue, the etiology 
varies in most of them, and only some samples are 
HCV-positive. In this part of our review we will focus 
our attention only on studies entirely dedicated to 
HCV-related HCC.
Varnholt et al[14] also proposed and validated a 
methodological approach for the study of miRNA 
expression in retrospective samples. The authors 
examined 80 miRNAs in a large set of formalin-fixed 
paraffin-embedded (FFPE) archival primary liver 
tumors derived from 39 HCV-positive patients, most of 
whom with cirrhosis. Interestingly, the tissue archive 
included premalignant dysplastic nodules (DNs) and 
HCCs, some of which were from the same patient. 
The authors assessed the availability and quality of 
RNA in FFPE tissues by comparing snap-frozen mouse 
liver tissues and FFPE samples, demonstrating that 
long-term storage did not affect the integrity of the 
miRNAs. Based on a wide-ranging approach performed 
on a small group of samples, the authors found 29 
dysregulated miRNAs, five of which were consistently 
altered in all tested samples (miR-122, miR-100, 
miR10a, miR-198 and miR-145). Further screening 
of these five miRNAs in a larger set of 52 primary 
tumors showed a significant upregulation of miR-122 
in DNs and in HCC samples, and a highly significant 
underexpression of miR-198 compared with normal 
liver parenchyma (Table 2). 
Interestingly, the dysregulated miRNAs described in 
this paper are located on a chromosome region linked 
to hepatocarcinogenesis[20,21]; however, the specific 
targets for most of these miRNAs are unknown.
Using miRNA whole-genome expression profiling 
to identify the urinary miRNA signature specific for 
HCV-associated HCC, Abdalla et al[22] analyzed 32 
HCV-associated HCC and 74 HCV-positive patients, 
comparing them to 12 healthy individuals. The 
authors focused their analysis on five miRNAs that 
were dysregulated and whose putative targets could 
play a role in hepatic carcinogenesis. Interestingly, for 
miR-618 and miR-650: the sensitivity and specificity of 
these miRNAs in detecting HCV-associated HCCs were 
described as having a higher predictive value than the 
α-feto protein levels.
A wide-ranging analysis was also performed by 
Diaz et al[23] using more than 2000 miRNAs and pre-
miRNAs on nine tumor samples and surrounding 
cirrhotic tissue. The results showed a specific 
association between 18 miRNAs and HCV-related liver 
cancer; these miRNAs were involved in the regulation 
of the p53 tumor suppressor, PTEN phosphatase and 
retinoic acid signaling, key factors implicated in cell 
growth that were previously associated with HCC[24,25]. 
Of note is the issue of miRNA 199a/b-3p, an miRNA 
highly expressed in normal liver and already found 
to be downregulated in HCCs of different etiology 
(HBV chronic infection and alcoholism). The authors 
confirmed a decrease in the expression levels of this 
miRNA in HCV-related HCC, suggesting that it has 
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Table 2  Highly dysregulated microRNAs identified in studies 
regarding hepatitis C virus-related hepatocellular carcinoma
Name In vitro/patient-derived samples Ref.
miR-24 Down In vitro [17]
mi-122 Up Patient derived samples [14]
miR-149 Up In vitro [17]
miR-181a Down In vitro [17]
miR-192/-215 Up In vitro [16]
miR-193b Up In vitro [19]
miR-194 Up In vitro [16]
miR-198 Down In vitro [14,15]
miR-198 Down Patient derived samples [14]
miR-199a Down Patients derived samples [23]
miR-210 Down In vitro [17]
miR-221 Down In vitro [17]
miR-320 Down In vitro [16]
miR-373* Up In vitro [17]
miR-455-3p Down In vitro [17]
miR-491 Down In vitro [16]
miR-638 Up In vitro [17]
miR-664 Down In vitro [17]
miR-887 Up In vitro [17]
miR-923 Down In vitro [17]
miR-940 Up In vitro [17]
miR-1181 Up In vitro [17]
miR-1234 Up In vitro [17]
miR-1469 Up In vitro [17]
Urinary
miR-516-5p Down Patient derived samples [22]
miR-532 Up Patient derived samples [22]
miR-618 Up Patient derived samples [22]
miR-625 Up Patient derived samples [22]
miR-650 Down Patient derived samples [22]
Table 1  MicroRNAs with an attributed biological significance in 
hepatitis C virus-related hepatocellular carcinoma development 
and behavior
Name Ref.
miR-192/-215 Enhancing HCV replication [16]
miR-193b Altered sensitivity to chemotherapy, 
inhibition of apoptosis
[19]
miR-198 Cell proliferation and migration [14,15]
miR-320 Cell proliferation [16]
miR-491 Cell proliferation, inhibition of apoptosis [16]
miR-24 Liver fibrosis [17]
miR-122 Modulation of HCV RNA expression [14]
miR-199a Poor survival, shorter time to disease 
recurrence, cell proliferation
[23]
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of investigating the role of lipid metabolism in HCV 
replication and infectivity, the authors established 
a Huh7.5 cell line transfected with mirR-27a and 
observed that its target genes are implicated in lipid 
biosynthesis and transport. Also, overexpression of 
miR-27a led to a decrease in viral infectivity and to 
an enhanced in vitro response to interferon (IFN). 
Therefore, the authors suggested that this negative 
feedback mechanism might contribute to maintenance 
of a low viral load and to escape from host immune 
surveillance, resulting in establishment of persistent 
chronic HCV infection, which is crucial for the 
development of HCC.
MICRORNAS IN HCV-RELATED 
LYMPHOMAS
There are few studies available about the involvement 
of miRNAs in the pathogenesis of HCV-related 
lymphoma. Conversely, there are several reports 
regarding deregulation of specific miRNAs in virus-
negative lymphomas, including some histotypes 
typically found to be associated with HCV infection 
[marginal zone lymphoma (MZL) and diffuse large B 
cell lymphoma (DLBCL)][30,31].
The first study introducing this issue was a large-
scale miRNA expression profiling analysis by Peveling-
Oberhag et al[32], who compared the expression of 
381 miRNAs in microdissected splenic marginal zone 
lymphoma (SMZL) (HCV-positive and -negative) and in 
normal splenic tissues. From this analysis, 12 miRNAs 
were identified as dysregulated in SMZLs compared 
with normal splenic controls. The majority of these 
miRNAs were already indicated as molecular players 
in cancers and lymphomas; however, one of these 
12 altered miRNAs, i.e., miR-26b, was significantly 
downregulated in HCV-positive lymphomas compared 
with HCV-negative SMZLs. MiR-26b is has tumor-
suppressive activity and its expression was found to 
be decreased only in HCV-related SMZLs; therefore, 
the authors speculated that a specific virus-related 
mechanism was involved in this particular miRNA.
These data were supported by a study performed 
in different categories of HCV subjects by Fognani et 
al[33] and Gragnani et al[34]. MiR-26b downregulation 
was reported in peripheral blood mononuclear cells 
(PBMCs) from HCV-related lymphoma patients and 
in PBMCs isolated from HCV-positive subjects with 
mixed cryoglobulinemia, a clinically benign condition 
that predisposes to the development of a frank 
malignancy[3]. 
The same authors also described a significant 
increase in the expressions of miR-21, miR-16 and 
miR-155 in PBMCs from only HCV-related NHL 
patients[33]. These three miRNAs have been previously 
termed “oncomiRNAs” because their overexpression 
has been associated with several cancers[32,35-37]. 
Taken together, these results indicated that miR-26b 
a role in inducing hepatic malignancy common to 
different causes. 
As previously mentioned in the section regarding in 
vitro studies, Salvi et al[18], starting from the screening 
of a library obtained in a cell line, focused their 
analysis of HCC tissue samples on selected miRNAs. 
MiR-24, miR-27a and miR-21 appeared to be the most 
frequently cloned miRNAs and their expression levels 
in human HCC tissues were dysregulated. In particular, 
the authors observed that miR-24 and miR-27a were 
significantly downregulated in HCCs from cirrhotic 
liver tissues compared with non-cirrhotic liver 
samples, while miR-21 was upregulated in HCC tissues 
compared with the corresponding peritumoral controls. 
The results described by Salvi et al[18] concerning 
miR-27a are controversial, because other authors 
have reported upregulation of the same miRNA in 
hepatocellular carcinoma cells[26]. 
On this topic, Murakami et al[27] analyzed miRNA 
expression in 24 HCC samples and 22 adjacent non-
tumor (NT) tissue samples, most of which were 
anti-HCV positive. They identified seven mature 
miRNAs (miR-18, miR-125a, miR-195, miR-199a, 
miR-199a*, miR-200a, miR-224) and one precursor 
miRNA (precursor miR-18) that were significantly and 
differentially expressed in the HCC and corresponding 
NT specimens. Furthermore, they used this result to 
build an algorithm that could predict the classification 
of samples into cancer and non-cancer groups. With 
the exception of one tumor sample, miRNA profiling 
allowed for accurate prediction of these groups, with 
an overall cross-validation accuracy of 97.8%. In 
addition, they compared miRNA expression in tumors 
in various differentiation states (well, moderately 
and poorly differentiated HCC) and found that the 
degree of tumor differentiation was inversely related 
to the expression levels of miR-92, miR-20, miR-18, 
suggesting that these miRNAs contribute to both 
tumorigenesis and the loss of tumor differentiation[27].
Regarding disease progression to hepatocellular 
carcinoma, a study by Ura et al[28] identified two 
categories of miRNAs, using a highly sensitive and 
quantitative RT-PCR method for miRNAs. The first 
category is associated with HBV or HCV infection; 
for example, miR-133b was repressed in the HCV 
group compared with the HBV group and also some 
hematopoietic-specific miRNAs, such as miR-142-
5p, were upregulated in the HCV group. The other 
miRNAs category comprises those associated with the 
stages of liver disease and are not virus-related (HBV 
vs. HCV). The authors found 23 miRNAs that could 
clearly distinguish chronic hepatitis from HCC and that 
might be good candidates for molecular targeting to 
prevent the occurrence of HCC, regulating a common 
signaling pathway underlying HCC-HBV and HCC-HCV 
development[28].
A very accurate work of Shirasaki et al[29] provided 
some hints at better clarifying the role of mirR-27a 
in HCV biology and HCC promotion. With the aim 
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is a key factor in HCV-related lymphomagenesis, 
and suggested that it might be useful as a peripheral 
biomarker. Recently, a study by Bruni et al[38] failed to 
report miR-26b dysregulation in paraffin-embedded 
samples derived from five HCV-positive NHL patients 
(as well as five HBV-positive and five HCV/HBV-
negative patients). The very limited number of cases 
could be the reason for these conflicting results. In 
their sampling, the authors observed a decreased 
level of miR-92a exclusively in HBV/HCV-negative NHL 
patients, while miR-30b was significantly increased 
only in HCV-positive samples. The analysis of a small 
subset of nodal marginal zone lymphomas highlighted 
three miRNAs that also seemed to be associated with 
HCV infection (miR-223, miR-29a and miR-29b). The 
authors themselves declared that caution is needed 
about the interpretation of such data, because of the 
limited number of analyzed samples. 
Another recently published study reported that, 
six and 14 out of 542 mature miRNAs, were over-
regulated and under-regulated, respectively, in HCV-
associated diffuse large B-cell lymphoma (DLBCL) 
compared with non-infected ones[39]. From the analysis 
of HCV-positive DLBCL, compared with non-infected 
DLBCL samples, a significant correlation was found 
between high miR-576-5p and miR-129-3p levels, low 
miR-522 and miR-512-3p levels, and germinal center 
B cell-like DLBCL immunophenotype. Moreover, miR-
25-5p was significantly correlated with poor prognosis 
and low miR-542-3p, miR-651-5p, miR-549a and high 
miR-369-5p correlated with advanced stage. 
In summary, all the reported results suggest that 
differences in miRNA expression exist between HCV-
related and HCV-negative NHLs, and further studies 
will be useful to ascertain if miRNAs are involved in the 
pathogenesis of HCV-related lymphomas and whether 
they can be used as biomarkers.
CONCLUSION
This brief review suggested that although miRNA 
profiling in HCV-related malignancies is an issue of 
high impact, there is little available research that is 
completely dedicated to this specific viral etiology. As 
is often common in miRNA expression studies, the 
different experimental approaches, limited number of 
tumor samples, the RNA used for normalization, the 
ethnicity of patients and, no less important, the kind 
of tissue used for comparison (normal liver or adjacent 
non tumor parenchyma) can lead to different and, 
occasionally, controversial results. 
From a technical point of view, different biases 
could affect miRNA quantification in biological samples, 
ranging from extraction problems[40,41] to incomplete 
hybridization during quantitative real time polymerase 
chain reaction or sequencing for miRNA quantitative 
profiling[42,43]. Although some high efficiency methods 
have been proposed recently[44,45], the application of 
circulating miRNAs in clinical practice still requires 
highly reproducible techniques for isolation and 
quantification of biological samples. For this reason, 
the interesting data reported in this review could 
represent a starting point for new studies aimed at the 
thorough investigation of targets and mechanisms of 
the suggested miRNAs, as well as for the identification 
of new epigenetic regulators.
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